Guideline Recommendations
The 2017 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS) Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (SCD) includes recommended use of the wearable cardioverter defibrillator (WCD) for a wide range of patients at risk for SCD, including post-MI, post-PCI, and NICM patients. The Guideline contains additional information about preventing SCD for patients with ischemic and non-ischemic heart disease, as well as shared decision making for patients at risk of SCD.
Review Guideline excerpts related to:
- Wearable Cardioverter Defibrillator
- Preventing SCD with HF Medications
- Shared Decision-Making
- Primary Prevention of SCD in Patients With Ischemic Heart Disease
- Secondary and Primary Prevention of SCD in Patients with NICM
Wearable Cardioverter-Defibrillator
Preventing SCD With HF Medications
Shared Decision-Making
Primary Prevention of SCD in Patients With Ischemic Heart Disease
Secondary and Primary Prevention of SCD in Patients with NICM
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force on clinical practices guidelines and the Heart Rhythm Society. Circulation. 2017; CIR.0000000000000549.